ABT - ABBOTT LABORATORIES
113.1
-0.510 -0.451%
Share volume: 4,603,868
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$113.61
-0.51
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-02-2024 | 07-31-2024 | 10-31-2024 | 02-21-2025 | 04-30-2025 | 07-30-2025 | 10-29-2025 | 02-20-2026 | |
| Assets | |||||||||
| Total Assets | 72.467 B | 73.017 B | 74.356 B | 81.414 B | 81.448 B | 83.999 B | 84.181 B | 86.713 B | |
| Current Assets | 22.376 B | 23.119 B | 23.802 B | 23.656 B | 23.153 B | 24.468 B | 24.839 B | 25.996 B | |
| Inventories | 6.827 B | 6.814 B | 6.813 B | 6.194 B | 6.639 B | 6.954 B | 6.708 B | 6.488 B | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 367.000 M | 232.000 M | 230.000 M | 351.000 M | 312.000 M | 331.000 M | 222.000 M | 417.000 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 6.284 B | 6.987 B | 7.558 B | 7.616 B | 6.532 B | 6.951 B | 7.511 B | 8.522 B | |
| Total Non-current Assets | 818.000 M | 877.000 M | 912.000 M | 886.000 M | 907.000 M | 958.000 M | 951.000 M | 918.000 M | |
| Property Plant Equipment | 10.107 B | 10.233 B | 10.621 B | 10.658 B | 10.932 B | 11.395 B | 11.504 B | 11.816 B | |
| Other Assets | 39.984 B | 39.665 B | 39.933 B | 47.100 B | 47.363 B | 48.136 B | 47.838 B | 48.901 B | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 72.467 B | 73.017 B | 74.356 B | 81.414 B | 81.448 B | 83.999 B | 84.181 B | 86.713 B | |
| Total liabilities | 33.424 B | 33.457 B | 34.328 B | 33.513 B | 32.384 B | 33.170 B | 32.917 B | 33.942 B | |
| Total current liabilities | 14.021 B | 13.760 B | 14.902 B | 14.157 B | 13.004 B | 13.439 B | 14.582 B | 16.496 B | |
| Accounts Payable | 4.178 B | 4.125 B | 4.034 B | 4.195 B | 4.214 B | 4.306 B | 4.123 B | 4.240 B | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 6.731 B | 0.000 | 0.000 | 0.000 | 7.550 B | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 12.576 B | 13.139 B | 12.825 B | 12.625 B | 12.736 B | 12.930 B | 11.596 B | 9.896 B | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 6.731 B | 0.000 | 0.000 | 0.000 | 7.550 B | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 38.810 B | 39.318 B | 39.796 B | 47.664 B | 48.811 B | 50.565 B | 50.954 B | 52.130 B | |
| Common stock | 24.726 B | 24.858 B | 25.020 B | 25.153 B | 25.125 B | 25.284 B | 25.412 B | 25.527 B | |
| Retained earnings | 38.011 B | 38.354 B | 39.056 B | 47.261 B | 47.715 B | 48.467 B | 49.103 B | 49.781 B |